HK Stock Market Move | HBM HOLDINGS-B (02142) rises by over 5%, incubated company signs CRH therapy cooperation agreement. Institutions say the scarcity value of the full human source is only on the heavy chain platform.

HBM HOLDINGS-B (02142) rose more than 5% in early trading, as of the time of writing, it is up by 3.85% at HK$5.4, with a trading volume of HK$22.7623 million. On the news front, HBM Pharmaceuticals recently announced that its innovative biotechnology company HBMAT, developed by the company, has signed an authorization and cooperation agreement with a business partner to advance a new therapy for treating various diseases involving corticotropin-releasing hormone (CRH). According to the agreement, the business partner has exclusive authorization to develop any pharmaceutical product containing or related to HBM9013 globally (excluding Greater China). Currently, the treatment options for CAH are limited, and HBM9013/HAT001 has shown strong efficacy in preclinical stages and is moving towards clinical development. Tianfeng pointed out that HBM Pharmaceuticals is a global innovative drug company in the clinical development stage, similar to antibody development platforms like Teneobio, and HBM's fully human single-chain platform is rare and valuable. The bank noted that HBM Pharmaceuticals, relying on the unique Harbour Mice platform, continues to produce high-potential molecules and has established extensive and frequent cooperation relationships with major pharmaceutical companies and innovative drug companies globally, with the number and amount of BD transactions ranking at the forefront of the industry. As of February 2025, the company has authorized development partnerships with more than a dozen well-known domestic and international pharmaceutical companies in the fields of ADC, antibodies, mRNA, cell therapy, artificial intelligence, and other areas, with multi-modal and multi-domain collaborations extending to various top partners at home and abroad.